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cal limb ischemia (Fountain stage III-IV) at admission;
length of stay no less than 2 weeks; conservative manage-
ment before surgery for one week at least. Patient charac-
teristics, length of stay (LOS) and discharge status were
assessed. Amputation was considered as treatment fail-
ure. Direct medical costs for pharmacotherapy, diagnos-
tic and treatment services were calculated.
RESULTS: Mean age of patients was 63,8  11,46 years;
84,8% were men. Duration of critical limb ischemia before
admission varied from two weeks to 14 months. Mean LOS
was 31  14 days. From 1 to 41 drugs (12,9  8,6) were
prescribed to patients during hospitalization. Most fre-
quently used drugs were pentoxifyllin and rheopolygluci-
num (77,1% and 58% of patients). Amputation was per-
formed on 41,9% patients, and angioplasty on 32,4%.
Median cost of treatment in the study group was 35 462,70
rub (1 222.9$). The median cost for treating patients with
amputation was 41 698,41 rub (1437.9$), and the median
cost for patients with angioplasty was 43 802,3 rub
(1510.4$). Median cost for patients without surgical inter-
vention was significantly lower - 14 423,4 rub (497.4$).
CONCLUSION: Common practice treatment for critical
limb ischemia in Moscow hospitals requires amputation
in 41,9 % of cases. Costs for management patients with
amputation do not differ from costs for management of
patients requiring angioplasty when all direct costs are
taken into account.
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During the development of hypertension, a progressive in-
crease in left ventricular mass (LVM) occurs. This hyper-
trophy is a predictor of the incidence of cardiovascular
disease and mortality. The great majority of anti-hyperten-
sive drugs lead to a reduction of LVM, thus improving the
prognosis. It is not known, however, which of these drugs
is the most cost-effective in terms of reduction of LVM.
OBJECTIVE: To investigate the cost of reducing LVM
by 1 gram with various agents during the treatment of
hypertension.
METHODS: Out of 28 trials published between 1984
and 1995, only 17 were included (528 patients, 21 drugs
from main anti-hypertensive classes including ACE inhib-
itors, or drug combinations) because they were of 12
months duration. The cost of drugs used (at Polish prices)
for the treatment period was divided by the change in
LVM in grams during that period.
RESULTS: The most cost-effective drugs in terms of
LVM reduction (USD/gram of muscle) were: atenolol
0,11; prazosin 0,34; hydralazine 0,44. Combinations of
anti-hypertensives were highly cost-effective: rezerpine 
hydrochlorothiazide 0,11; atenolol  indapamide 0,92.
CONCLUSION: These results may serve as a guide in deci-
sion-making for the choice of treatment and reimbursement.
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OBJECTIVES: A Chest Pain Unit (CPU) with a diagnos-
tic algorithm employing troponin T (TnT) assay was im-
plemented in a public hospital in Hong Kong in February
2000. The aim of this study was to compare the cost-
effectiveness in risk stratification of chest pain (CP) pa-
tients before and after the implementation of a CPU from
the perspective of a public-health organization.
METHODS: Medical records of patients with CP pre-
sented to the Accident & Emergency (A&E) department in
November 1999 (pre-CPU) and November 2000 (post-
CPU) were reviewed. Patients with non-diagnostic CP
were recruited. Resource utilization for CP diagnosis was
retrieved from medical records. The clinical outcome (30-
day post-discharge re-admission or death secondary to car-
diac causes) was obtained from follow-up phone interview
and hospital records for patients discharged home from
A&E or CPU. Cost-effectiveness ratios (CERs) for the two
study periods and incremental CER were calculated.
RESULTS: There were 689 and 836 patients presented to
A&E with CP in November 1999 and November 2000,
respectively. The percentage of patients discharged from
A&E was higher in the pre-CPU group (64.7% vs.
50.5%, p  .001). A total of 529 patients in the pre-CPU
group and 581 patients in the pre-CPU group with non-
diagnostic CP were recruited. The cost of differential di-
agnosis for CP per patient was HK$2,934 (1USD  7.8
HKD) in the pre-CPU group and HK$3,641 in the post-
CPU group. The 30-day, post-discharge, cardiac-event
rate was 8.4% in pre-CPU group vs. 5.6% in post-CPU
group (p  .172). The CERs were HK$3,203 (pre-CPU)
and HK$3,857 (post-CPU) per patient per 30-day, car-
diac-event-free period. The incremental CER for the post-
CPU group was HK$25,245 per additional patient per
30-day, cardiac-event-free period.
CONCLUSION: Based on the data obtained, the imple-
mentation of a CPU appears to be able to reduce the 30-
day cardiac event rate with an incremental CER of
HK$25,245.
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